August 4, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), ('Shire' / the 'Group') in accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, is publishing its Half-yearly Report for the six months ended June 30, 2017.

On August 3, 2017, the Group announced its results for the same period.

Stephen Williams
Deputy Company Secretary

Download the full Half-yearly Report

For further information please contact:

NOTES TO EDITORS

About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

www.shire.com

Shire plc published this content on 04 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 04 August 2017 07:23:09 UTC.

Original documenthttps://www.shire.com/en/newsroom/2017/august/2bnfkd

Public permalinkhttp://www.publicnow.com/view/3293A1732816CCAEECCAEC3B9B44EE6478B77EDE